F. Hoffmann-La Roche had two patents in mobile during Q4 2023. The patent filed by F. Hoffmann-La Roche Ltd in Q4 2023 relates to an alert system for informing users about their blood glucose levels, with alerts ranging from low to high priority. The alerts are communicated through user devices like smartphones or smart watches, and can be modified to increase the likelihood of user acknowledgment. The intensity and modality of alerts are adjusted based on user response to previous alerts, ensuring timely and effective communication. GlobalData’s report on F. Hoffmann-La Roche gives a 360-degreee view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
F. Hoffmann-La Roche grant share with mobile as a theme is 50% in Q4 2023. Grant share is based on the ratio of number of grants to total number of patents.
Recent Patents
Application: Medical device alert, optimization, personalization, and escalation (Patent ID: US20230351867A1)
See Also:
The patent filed by F. Hoffmann-La Roche Ltd. describes a method and apparatus for delivering diabetes-related alerts to users based on user-specific criteria such as age and gender. The alerts are communicated through a user device like a smartphone or smartwatch, with modifications made to the alert intensity or sensory channel to ensure prompt user acknowledgment. The system uses facial recognition technology to determine user-specific criteria and can adjust the alert volume based on the user's hearing ability. Additionally, the system can store user-specific criteria for future use and includes a testing mechanism to adjust the alert volume level effectively.
The method and apparatus outlined in the patent involve receiving images of the user and comparing them with images of other individuals to determine user-specific criteria like age and gender. The system can detect triggering events indicating hypoglycemic or hyperglycemic states to deliver timely alerts. By utilizing facial features for comparison and employing a regression model for determining user-specific criteria, the system ensures accurate alert delivery. The apparatus includes a processor and memory for processing and storing user-specific criteria, respectively, and can adjust the alert volume level based on the user's hearing ability. Overall, the patent presents a comprehensive system for delivering diabetes-related alerts tailored to individual users' needs and preferences.
To know more about GlobalData’s detailed insights on F. Hoffmann-La Roche, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
